<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02398513</url>
  </required_header>
  <id_info>
    <org_study_id>15823</org_study_id>
    <nct_id>NCT02398513</nct_id>
  </id_info>
  <brief_title>Regorafenib Phase I Study in Mainland Chinese Patients</brief_title>
  <official_title>Uncontrolled, Open-label, Non-randomized, Phase I Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Regorafenib in Chinese Patients (China Mainland) With Advanced, Refractory Solid Tumors)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to define the pharmacokinetic of Regorafenib&#xD;
      administered orally as a single agent in Chinese patients with advance solid tumors.&#xD;
&#xD;
      The second objective include the evaluation of safety, tolerability, and efficacy of Chinese&#xD;
      patents treated with Regorafenib&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (maximum drug concentration in plasma)</measure>
    <time_frame>Cycle 0 day 1, 0、0.5、1、2、3、4、6、8、12、24、36、48、72、96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24) (AUC from time 0 h to time 24 h post-administration)</measure>
    <time_frame>Cycle 0 day1, 0、0.5、1、2、3、4、6、8、12、24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast) (AUC from time zero to the last data point&gt;LLOQ)</measure>
    <time_frame>Cycle0 day 1, 0、0.5、1、2、3、4、6、8、12、24、36、48、72、96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax.ss (Cmax at steady-state during a dosage interval)</measure>
    <time_frame>Cycle 1 day 21, 0,0.5,1,2,3,4,6,8,12,24,36,48,72,96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt.ss (AUC for the dosing interval at steady-state)</measure>
    <time_frame>cycle 1 day 21 0,0.5,1,2,3,4,6,8,12,24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response base don RECIST 1.1 criteria</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Oncology</condition>
  <arm_group>
    <arm_group_label>Regorafenib (Stivarga, BAY73-4506)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in the study will start treatment with Regorafenib160 mg (given by four 40 mg tablets of Regorafenib) on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, Regorafenib 160 mg QD will be administered for 21 days, followed by 7 days off treatment. Treatment with Regorafenib will continue until the patient either progresses or meets one of the criteria for withdrawal prespecified in the study protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib (Stivarga, BAY73-4506)</intervention_name>
    <description>Regorafenib 160 mg per oral</description>
    <arm_group_label>Regorafenib (Stivarga, BAY73-4506)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent (IC) obtained before any study specific procedure. Patients&#xD;
             must be able to understand and be willing to sign the written informed consent&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed,refractory,locally advanced or&#xD;
             metastatic solid tumors who are not candidates for standard therapy or in whom the&#xD;
             specific clinical indications for which Regorafenib is approved elsewhere in the world&#xD;
             is considered an appropriate treatment option.&#xD;
&#xD;
          -  Male or female Chinese patients living in China mainland &gt;= 18 years&#xD;
&#xD;
          -  Patients must have measurable or non-measurable disease according to RECIST, version&#xD;
             1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status (ECOG-PS 0 - 1)&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 33 kg/m2 inclusive&#xD;
&#xD;
          -  Adequate bone marrow, liver, and renal function as assessed by the following&#xD;
             laboratory requirements to be conducted within 7 days prior to dosing:&#xD;
&#xD;
               -  Platelet count &gt;= 100,000/cubic millimeters (mm3), hemoglobin (Hb) &gt;= 9 g/dl,&#xD;
                  leukocyte count &gt; 3,000/mm3, absolute neutrophil count (ANC) &gt;=1,500/mm3.&#xD;
                  Transfusion to meet the inclusion criteria will not be allowed.&#xD;
&#xD;
               -  Total bilirubin &lt;= 1.5 x the upper limit of normal (ULN).&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt;= 3.0 x ULN&#xD;
                  (&lt;= 5 x ULN for patients with liver involvement of their cancer)&#xD;
&#xD;
               -  Alkaline phosphatase limit &lt;= 2.5 x ULN (&lt;= 5 x ULN for patients whose cancer&#xD;
                  involves their liver and/or bone)&#xD;
&#xD;
               -  Lipase &lt;= 1.5 x ULN&#xD;
&#xD;
               -  Serum creatinine &lt;= 1.5 times ULN and estimated creatinine clearance (CLcr) &gt;= 30&#xD;
                  mL/min according to the Cockroft-Gault formula&#xD;
&#xD;
          -  International normalized ratio (INR) &lt;= 1.5 x ULN and partial thromboplastin time&#xD;
             (PTT) or activated partial thromboplastin time (aPTT) &lt;= 1.5 x ULN. Patients being&#xD;
             treated with anticoagulant, e.g. warfarin or heparin, will be allowed to participate&#xD;
             provided no prior evidence of an underlying abnormality in these parameters exists.&#xD;
             Close monitoring of at least weekly evaluations will be performed until INR and PTT&#xD;
             are stable based on a pre-dose measurement as defined by the local standard of care.&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  Women of childbearing potential must have a pregnancy test performed a maximum of 7&#xD;
             days before start of study treatment, and a negative result must be documented before&#xD;
             start of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with Regorafenib&#xD;
&#xD;
          -  Patients unable to swallow and retain oral medications&#xD;
&#xD;
          -  Any other malignant disease treated &lt; 3 years prior to study entry, except cervical&#xD;
             carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors&#xD;
             (Staging: Ta, Tis and T1)&#xD;
&#xD;
          -  Symptomatic metastatic brain or meningeal tumors if the patient is &lt; 6 months from&#xD;
             definitive therapy, has evidence of tumor growth on an imaging study within 4 weeks&#xD;
             prior to study entry and is on dexamethasone and not clinically stable with respect to&#xD;
             the tumor at the time of study entry.&#xD;
&#xD;
          -  Major surgical procedure, or significant traumatic injury within 28 days before start&#xD;
             of study medication&#xD;
&#xD;
          -  History of organ allograft&#xD;
&#xD;
          -  Non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure &gt;150 millimeter of mercury (mmHg)&#xD;
             or diastolic blood pressure &gt;90 mmHg despite optimal medical management)&#xD;
&#xD;
          -  Persistent proteinuria &gt; 3.5 g/24 hours measured by urine protein-creatinine ratio&#xD;
             from a random urine sample (&gt;=Grade 3, NCI-CTCAE v 4.03).&#xD;
&#xD;
          -  History of cardiac disease: congestive heart failure (CHF) &gt;=NYHA (New York Heart&#xD;
             Association) Class II. Active coronary artery disease unstable angina (angina symptoms&#xD;
             at rest) or new-onset angina (within last 3 months) or myocardial infarction (MI)&#xD;
             within past 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>July 29, 2016</last_update_submitted>
  <last_update_submitted_qc>July 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

